IGF-1 z score meaning starts with comparison. It describes how far your blood result sits above or below the lab's expected center for your age and sex. It isn't a health grade or a medicine target.
IGF-1 means insulin-like growth factor 1, a chemical messenger involved in growth. A standard deviation is a statistical unit describing how widely results spread. The z-score counts those units. SDS, short for standard deviation score, means the same thing. The IGF-1 discovery story explains how the growth signal and its molecule were identified.
IGF-1 z score meaning: three parts of one report
The amount measured and the score calculated from it answer different questions. The reference population—the comparison group used by the lab—connects them.
Chanson and colleagues' 2016 VARIETE study in the Journal of Clinical Endocrinology & Metabolism tested samples from 911 healthy French adults. It used six assays, meaning laboratory testing methods (the study).
| Part of the report | What it tells you | Where the study fits |
|---|---|---|
| Raw concentration, in ng/mL | The amount measured; ng/mL means nanograms per milliliter | The six methods measured the same adult samples |
| Assay-specific reference population | Which comparison data belong with that testing method | The 911-adult group supplied age- and sex-specific models for each assay |
| Standardized value, called z-score or SDS | Position within that model, without concentration units | The researchers calculated scores after adjusting the shape of the data |
The comparison depends on the testing method as well as age. Our IGF-1 levels by age guide covers age bands and high or low results.
For someone discussing sermorelin, a medicine studied for signaling growth-hormone release, that distinction matters before any follow-up comparison. The clinician needs the starting report's method and reference data, not just its largest printed number.
Why a simple online formula can miss the point
A positive score sits above the expected center; a negative score sits below it. Zero means the center of the comparison model, not an absence of IGF-1. The distance describes position, not the amount of hormone added or removed.
The calculation isn't always “subtract an average, then divide.” In the VARIETE study, the researchers mathematically reshaped unevenly spread results before building curves for each age, sex and assay.
They deliberately omitted raw averages and standard deviations from their reference table to prevent incorrect score calculations.
Labcorp's calculator instructions make the practical limit clear: its calculation is intended for its own specified testing method. A number entered into an unrelated calculator can produce a precise-looking answer using the wrong comparison.
Six tests did not give identical standardized answers
Putting results on a shared scale helped with interpretation. It didn't remove every difference between methods.
In Chanson's study, weighted kappa—a statistic measuring agreement after allowing for chance—ranged from 0.38 to 0.70 between test pairs. It isn't a patient's z-score.
Mavromati and colleagues then examined 102 patients being evaluated or monitored for growth-hormone disorders. Their 2017 paper, also in the Journal of Clinical Endocrinology & Metabolism, used the same six assays and the earlier reference data (the patient study).
Both measured concentrations and calculated scores still varied. Agreement between test pairs ranged from 0.50 to 0.81 on that same statistic. The authors argued for using the same assay throughout a patient's follow-up.
For a person prescribed sermorelin, this gives the clinician a reason to check whether repeat results are comparable before interpreting a rise. These were studies of laboratory measurement, not trials showing benefits from sermorelin.
A September 2026 paper explains the reporting checks
As of November 12, 2026, the day this article was written, a September 3, 2026 paper describes checks for adding z-scores to IGF-1 reports. Olgaard and colleagues' report in the Journal of Applied Laboratory Medicine covers matching reference data, testing the calculation in laboratory software and comparing results with reference laboratories. It describes one laboratory's approach, not a new treatment target or a guarantee that every laboratory calculates scores identically.
That distinction matters when a report adds a score that wasn't printed before. A new line on the report can reflect a reporting change. It doesn't, by itself, show that the body's hormone activity changed.
What makes a follow-up comparison useful
A useful comparison keeps the collection date, concentration, units, score, reference range and testing method together. The lab's name alone may leave a question: was the same assay used both times?
If the method changed, the provider can ask the laboratory how the old and new results relate. A changed number needs that context before it becomes a treatment decision. Standardization makes the report easier to read; it doesn't replace the details behind it.
The clinical context matters too. MedlinePlus explains that IGF-1 testing helps assess growth-hormone disorders and that further tests may be needed. Symptoms and the reason for testing belong beside the score.
For sermorelin follow-up, comparable measurements help a provider interpret a trend. They don't establish better sleep, strength or recovery. Those are separate outcomes, and a higher score alone doesn't settle them. The questions to ask before sermorelin guide connects lab review with the goal and follow-up plan.
Where prescribing fits
A laboratory comparison and a prescription decision are separate steps. The score describes a result; the provider decides whether a medicine fits the person's history and proposed goal. The prescriber sets the actual dose and any changes.
Compounding means preparing a medicine for an individual prescription. Sermorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication. That is different from an FDA-approved product: the formulation offered here is not FDA-approved.
The compounded medicine is different from Geref, a once-marketed FDA-approved sermorelin product that has since been discontinued. FDA's March 4, 2013 notice says it wasn't withdrawn for safety or effectiveness.
As of November 12, 2026, the day this article was written, FDA explains that it doesn't verify compounded drugs' safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies.





